Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?
Ehab Bakbak, Daniella C. Terenzi, Justin Z. Trac, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 22, Iss. 4, pp. 1171-1188
Closed Access | Times Cited: 25

Showing 25 citing articles:

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao, Minghe Wang, Zhitong Wen, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 253
Predicting and preventing heart failure in type 2 diabetes
Ambarish Pandey, Muhammad Shahzeb Khan, Kershaw V. Patel, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 8, pp. 607-624
Closed Access | Times Cited: 36
Endothelial Dysfunction in Obesity and Therapeutic Targets
Atilla Engin
Advances in experimental medicine and biology (2024), pp. 489-538
Closed Access | Times Cited: 10
Unlocking the Multifaceted Roles of GLP-1: Physiological Functions and Therapeutic Potential.
Tohada M. AL‐Noshokaty, Rehab Abdelhamid, Nourhan M. Abdelmaksoud, et al.
Toxicology Reports (2025) Vol. 14, pp. 101895-101895
Open Access | Times Cited: 1
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials
Subodh Verma, Meena Bhatta, Melanie J. Davies, et al.
EClinicalMedicine (2022) Vol. 55, pp. 101737-101737
Open Access | Times Cited: 38
GLP-1 receptor agonist as a modulator of innate immunity
Jun Chen, Aihua Mei, Yingying Wei, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 36
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
Francesco Cosentino, Subodh Verma, Philip Ambery, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4141-4156
Open Access | Times Cited: 18
Primary Occurrence of Cardiovascular Events After Adding Sodium–Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
Tadarro L. Richardson, Alese E. Halvorson, Amber J. Hackstadt, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 6, pp. 751-760
Open Access | Times Cited: 11
GLP-1RA therapy increases circulating vascular regenerative cell contentin people living with type 2 diabetes
Brady Park, Aishwarya Krishnaraj, Hwee Teoh, et al.
AJP Heart and Circulatory Physiology (2024) Vol. 327, Iss. 2, pp. H370-H376
Closed Access | Times Cited: 3
The link between hyperuricemia and diabetes: insights from a quantitative analysis of scientific literature
Lili Ma, Jing Wang, Li Ma, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access
Modern Methods of Pharmacological Correction of Diabetic Polyneuropathy
Valery Tsepelev, И. О. Масалева, N.V. Boldina, et al.
Ural Medical Journal (2025) Vol. 24, Iss. 1, pp. 142-158
Closed Access
Vascular repair and regeneration in cardiometabolic diseases
David A. Hess, Subodh Verma, Deepak L. Bhatt, et al.
European Heart Journal (2021) Vol. 43, Iss. 6, pp. 450-459
Closed Access | Times Cited: 18
GLP1R (glucagon-like-peptide-1 incretin receptor), diabetes and obesity phenotypes: An in silico approach revealed new pathogenic variants
Vinicius Matheus Knihs, Fabíola Branco Filippin-Monteiro
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 2, pp. 102956-102956
Closed Access | Times Cited: 2
Comparative analysis of newer classes of antidiabetics and the concept of pharmaceutical care – dealing with therapeutic problems
Anna Peneva, Milen Dimitrov, Valentina Petkova
Pharmacia (2024) Vol. 71, pp. 1-8
Open Access | Times Cited: 2
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
Mengqing Zhang, Chu Lin, Xiaoling Cai, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 806-815
Closed Access | Times Cited: 2
A Review of Recent Pharmacological Advances in the Management of Diabetes-Associated Peripheral Neuropathy
Osman Syed, Predrag Jancic, Nebojša Nick Knežević
Pharmaceuticals (2023) Vol. 16, Iss. 6, pp. 801-801
Open Access | Times Cited: 5
Anti-Inflammatory Effects of GLP-1R Activation in the Retina
Alessandra Puddu, Davide Maggi
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12428-12428
Open Access | Times Cited: 8
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
Eleonora Panfili, Giulio Frontino, Maria Teresa Pallotta
Frontiers in Clinical Diabetes and Healthcare (2023) Vol. 4
Open Access | Times Cited: 4
Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity
Daniella C. Terenzi, Ehab Bakbak, Hwee Teoh, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 18, pp. 2858-2874
Open Access | Times Cited: 3
Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies
Qingyi Zhan, Wenjing Peng, Siqi Wang, et al.
Journal of Cardiovascular Translational Research (2022) Vol. 16, Iss. 2, pp. 310-326
Closed Access | Times Cited: 5
Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights
Naveed Sattar, Stefan D. Anker, Javed Butler, et al.
European Heart Journal (2021) Vol. 43, Iss. 31, pp. 2968-2970
Closed Access | Times Cited: 7
Evidence of Bariatric Surgery Benefits Cardiac Function in Non-HFpEF Patients with Obesity: a Meta-Analysis
Shi‐jing Lu, Taotao Zhang, Xiang-wen Zhang, et al.
Obesity Surgery (2023) Vol. 33, Iss. 11, pp. 3353-3361
Closed Access | Times Cited: 2
GLP-1 Agonists
Eloise Stanton, Artur Manasyan, Rakhi Banerjee, et al.
Annals of Plastic Surgery (2024)
Closed Access
Obesity, Cardiometabolic Syndrome and Bariatric Surgery
Susmita Sinha, Mahendra Narwaria, Mainul Haque
Advances in Human Biology (2023)
Closed Access
Efeitos prospectivos da cirurgia bariátrica em marcadores de ateroesclerose, uma revisão sistemática do cenário atual / Prospective effects of bariatric surgery on atherosclerosis markers, a systematic review of the current scenario
Victor Hugo Nunes De Oliveira, Júlia Félix Almeida Rosário, Tatiane da Cunha Marques Gonçalves, et al.
Brazilian Journal of Health Review (2022) Vol. 5, Iss. 3, pp. 8886-8897
Open Access
Page 1

Scroll to top